What is Septerna?
Headquartered in South San Francisco, Septerna is a pioneering biotechnology enterprise dedicated to unlocking the therapeutic potential of G protein-coupled receptors (GPCRs). The company utilizes its proprietary Native Complex Platform to engineer oral small-molecule drug candidates that address high-unmet needs in endocrinology, immunology, inflammation, and metabolic diseases. By focusing on the structural complexity of GPCRs, Septerna distinguishes itself from traditional drug discovery models, positioning its pipeline as a transformative force in the biopharmaceutical sector. The company's strategic approach combines rigorous scientific validation with a robust operational framework, ensuring that its therapeutic candidates are optimized for clinical success and long-term patient impact.
How much funding has Septerna raised?
Septerna has raised a total of $538M across 3 funding rounds:
Series A
$100M
Series B
$150M
Stock Offering
$288M
Series A (2022): $100M with participation from Invus Financial Advisors, Third Rock Ventures, BVF Partners, and Samsara BioCapital
Series B (2023): $150M led by RA Capital Management, Third Rock Ventures, and Samsara BioCapital
Stock Issuance/Offering (2024): $288M supported by Cowen, Cantor Fitzgerald, and Wells Fargo Securities
Key Investors in Septerna
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its TechAtlas think tank to analyze clinical data.
Third Rock Ventures
A healthcare venture firm focused on disruptive science and medicine, dedicated to discovering and building companies that make a dramatic difference in patient lives.
Samsara BioCapital
A firm focused on creating transformative therapeutics by partnering with scientists and drug developers to drive innovation in the biopharmaceutical sector.
What's next for Septerna?
With the recent influx of capital, Septerna is poised to transition into a more mature phase of its corporate lifecycle, focusing on the advancement of its lead candidates through critical clinical milestones. The company will likely prioritize the expansion of its internal research capabilities while simultaneously exploring strategic partnerships to broaden the reach of its Native Complex Platform. As Septerna continues to scale, the focus will remain on maintaining its competitive edge in GPCR research, ensuring that its pipeline remains a cornerstone of its long-term growth strategy. Investors and industry stakeholders will be closely monitoring the company's progress as it moves toward potential commercialization and further therapeutic breakthroughs.
See full Septerna company page
